Are You Reducing Itch and Improving Quality of Life in Your Patients with Prurigo Nodularis?
Pre-test
Questions marked with a
*
are required
100%
Contact Information
First Name
Last Name
Email Address
Which of the following characteristics specific to persons of color would alert you to a diagnosis of prurigo nodularis in this population?
Persistent pruritic
Crusting due to scratching
Larger, darker, and densely fibrotic nodules
Symmetrical distribution of nodules
Which of the following represents the right combination of investigational agent in clinical trials for the treatment of prurigo nodularis and its route of administration?
Abrocitinib and subcutaneous delivery
Povorcitinib and IV delivery
Barzolvolimab and oral delivery
Vixarelimab and subcutaneous delivery
Ana is an African-American in her mid-20s with prurigo nodularis complains of constant sleep deprivation and nocturnal itching. She displays signs of anxiety and depression, possibly related to her insomnia and constant embarrassment due to the dark and thick fibrotic nodules on her legs and hands. In the past, she has been treated with various topical corticosteroids, phototherapy, antidepressants, and antihistamines. Most recently, she was treated with dupilumab but while it reduced the size of nodules, she did not get sufficient itch relief. What might be your next treatment option?
Methotrexate
Nemolizumab
Participate in a clinical trial
Higher-dose antihistamine
Done
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close